Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial.
Adolescent
Adult
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
Botswana
/ epidemiology
Circumcision, Male
/ statistics & numerical data
Female
HIV Infections
/ diagnosis
HIV-1
/ physiology
Humans
Longitudinal Studies
Male
Mass Screening
Middle Aged
Prevalence
Surveys and Questionnaires
Viral Load
Young Adult
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
01
08
2019
revised:
20
03
2020
accepted:
20
03
2020
pubmed:
7
6
2020
medline:
28
8
2020
entrez:
7
6
2020
Statut:
ppublish
Résumé
In settings with high HIV prevalence and treatment coverage, such as Botswana, it is unknown whether uptake of HIV prevention and treatment interventions can be increased further. We sought to determine whether a community-based intervention to identify and rapidly treat people living with HIV, and support male circumcision could increase population levels of HIV diagnosis, treatment, viral suppression, and male circumcision in Botswana. The Ya Tsie Botswana Combination Prevention Project study was a pair-matched cluster-randomised trial done in 30 communities across Botswana done from Oct 30, 2013, to June 30, 2018. 15 communities were randomly assigned to receive HIV prevention and treatment interventions, including enhanced HIV testing, earlier antiretroviral therapy (ART), and strengthened male circumcision services, and 15 received standard of care. The first primary endpoint of HIV incidence has already been reported. In this Article, we report findings for the second primary endpoint of population uptake of HIV prevention services, as measured by proportion of people known to be HIV-positive or tested HIV-negative in the preceding 12 months; proportion of people living with HIV diagnosed and on ART; proportion of people living with HIV on ART with viral suppression; and proportion of HIV-negative men circumcised. A longitudinal cohort of residents aged 16-64 years from a random, approximately 20% sample of households across the 15 communities was enrolled to assess baseline uptake of study outcomes; we also administered an end-of-study survey to all residents not previously enrolled in the longitudinal cohort to provide study end coverage estimates. Differences in intervention uptake over time by randomisation group were tested via paired Student's t test. The study has been completed and is registered with ClinicalTrials.gov (NCT01965470). In the six communities participating in the end-of-study survey, 2625 residents (n=1304 from standard-of-care communities, n=1321 from intervention communities) were enrolled into the 20% longitudinal cohort at baseline from Oct 30, 2013, to Nov 24, 2015. In the same communities, 10 791 (86%) of 12 489 eligible enumerated residents not previously enrolled in the longitudinal cohort participated in the end-of-study survey from March 30, 2017, to Feb 25, 2018 (5896 in intervention and 4895 in standard-of-care communities). At study end, in intervention communities, 1228 people living with HIV (91% of 1353) were on ART; 1166 people living with HIV (88% of 1321 with available viral load) were virally suppressed, and 673 HIV-negative men (40% of 1673) were circumcised in intervention communities. After accounting for baseline differences, at study end the proportion of people living with HIV who were diagnosed was significantly higher in intervention communities (absolute increase of 9% to 93%) compared with standard-of-care communities (absolute increase of 2% to 88%; prevalence ratio [PR] 1·08 [95% CI 1·02-1·14], p=0·032). Population levels of ART, viral suppression, and male circumcision increased from baseline in both groups, with greater increases in intervention communities (ART PR 1·12 [95% CI 1·07-1·17], p=0·018; viral suppression 1·13 [1·09-1·17], p=0·017; male circumcision 1·26 [1·17-1·35], p=0·029). It is possible to achieve very high population levels of HIV testing and treatment in a high-prevalence setting. Maintaining these coverage levels over the next decade could substantially reduce HIV transmission and potentially eliminate the epidemic in these areas. US President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention.
Sections du résumé
BACKGROUND
In settings with high HIV prevalence and treatment coverage, such as Botswana, it is unknown whether uptake of HIV prevention and treatment interventions can be increased further. We sought to determine whether a community-based intervention to identify and rapidly treat people living with HIV, and support male circumcision could increase population levels of HIV diagnosis, treatment, viral suppression, and male circumcision in Botswana.
METHODS
The Ya Tsie Botswana Combination Prevention Project study was a pair-matched cluster-randomised trial done in 30 communities across Botswana done from Oct 30, 2013, to June 30, 2018. 15 communities were randomly assigned to receive HIV prevention and treatment interventions, including enhanced HIV testing, earlier antiretroviral therapy (ART), and strengthened male circumcision services, and 15 received standard of care. The first primary endpoint of HIV incidence has already been reported. In this Article, we report findings for the second primary endpoint of population uptake of HIV prevention services, as measured by proportion of people known to be HIV-positive or tested HIV-negative in the preceding 12 months; proportion of people living with HIV diagnosed and on ART; proportion of people living with HIV on ART with viral suppression; and proportion of HIV-negative men circumcised. A longitudinal cohort of residents aged 16-64 years from a random, approximately 20% sample of households across the 15 communities was enrolled to assess baseline uptake of study outcomes; we also administered an end-of-study survey to all residents not previously enrolled in the longitudinal cohort to provide study end coverage estimates. Differences in intervention uptake over time by randomisation group were tested via paired Student's t test. The study has been completed and is registered with ClinicalTrials.gov (NCT01965470).
FINDINGS
In the six communities participating in the end-of-study survey, 2625 residents (n=1304 from standard-of-care communities, n=1321 from intervention communities) were enrolled into the 20% longitudinal cohort at baseline from Oct 30, 2013, to Nov 24, 2015. In the same communities, 10 791 (86%) of 12 489 eligible enumerated residents not previously enrolled in the longitudinal cohort participated in the end-of-study survey from March 30, 2017, to Feb 25, 2018 (5896 in intervention and 4895 in standard-of-care communities). At study end, in intervention communities, 1228 people living with HIV (91% of 1353) were on ART; 1166 people living with HIV (88% of 1321 with available viral load) were virally suppressed, and 673 HIV-negative men (40% of 1673) were circumcised in intervention communities. After accounting for baseline differences, at study end the proportion of people living with HIV who were diagnosed was significantly higher in intervention communities (absolute increase of 9% to 93%) compared with standard-of-care communities (absolute increase of 2% to 88%; prevalence ratio [PR] 1·08 [95% CI 1·02-1·14], p=0·032). Population levels of ART, viral suppression, and male circumcision increased from baseline in both groups, with greater increases in intervention communities (ART PR 1·12 [95% CI 1·07-1·17], p=0·018; viral suppression 1·13 [1·09-1·17], p=0·017; male circumcision 1·26 [1·17-1·35], p=0·029).
INTERPRETATION
It is possible to achieve very high population levels of HIV testing and treatment in a high-prevalence setting. Maintaining these coverage levels over the next decade could substantially reduce HIV transmission and potentially eliminate the epidemic in these areas.
FUNDING
US President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention.
Identifiants
pubmed: 32504575
pii: S2352-3018(20)30103-X
doi: 10.1016/S2352-3018(20)30103-X
pmc: PMC7864245
mid: NIHMS1661470
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT01965470']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e422-e433Subventions
Organisme : NIAID NIH HHS
ID : K23 AI091434
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127271
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG065276
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : Wellcome Trust
ID : 107752/Z/15/Z
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI051164
Pays : United States
Organisme : NICHD NIH HHS
ID : K23 HD070774
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW000004
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236546
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI136947
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222147
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI131928
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI104459
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
PLoS One. 2019 Nov 25;14(11):e0225076
pubmed: 31765394
AIDS Behav. 2019 Apr;23(4):875-882
pubmed: 30673897
N Engl J Med. 2019 Jul 18;381(3):219-229
pubmed: 31314966
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29314658
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
MMWR Morb Mortal Wkly Rep. 2017 Dec 01;66(47):1285-1290
pubmed: 29190263
BMC Infect Dis. 2011 Sep 26;11:253
pubmed: 21943076
Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
PLoS One. 2011;6(11):e27561
pubmed: 22140449
BMJ Open. 2018 Sep 1;8(8):e021835
pubmed: 30173159
Lancet. 2010 Jun 12;375(9731):2092-8
pubmed: 20537376
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
Adolesc Health Med Ther. 2018 Dec 04;9:211-235
pubmed: 30584383
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
JMIR Res Protoc. 2017 Mar 08;6(3):e22
pubmed: 28274904